119 related articles for article (PubMed ID: 27034430)
1. First report of MYD88 L265P somatic mutation in IgM-associated light-chain amyloidosis.
Chakraborty R; Novak AJ; Ansell SM; Muchtar E; Kapoor P; Hayman SR; Dispenzieri A; Buadi FK; Lacy MQ; King RL; Gertz MA
Blood; 2016 Jun; 127(23):2936-8. PubMed ID: 27034430
[No Abstract] [Full Text] [Related]
2. First report of MYD88
Chakraborty R; Novak AJ; Ansell SM; Muchtar E; Kapoor P; Hayman SR; Dispenzieri A; Buadi FK; Lacy MQ; King RL; Gertz MA
Amyloid; 2017 Mar; 24(sup1):42-43. PubMed ID: 28434299
[No Abstract] [Full Text] [Related]
3. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.
Sidana S; Larson DP; Greipp PT; He R; McPhail ED; Dispenzieri A; Murray DL; Dasari S; Ansell SM; Muchtar E; Gonsalves WI; Kourelis TV; Ramirez-Alvarado M; Kapoor P; Rajkumar SV; Lacy MQ; Buadi FK; Leung N; Kyle RA; Kumar SK; King RL; Gertz MA
Leukemia; 2020 May; 34(5):1373-1382. PubMed ID: 31780812
[TBL] [Abstract][Full Text] [Related]
4. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.
Varettoni M; Arcaini L; Zibellini S; Boveri E; Rattotti S; Riboni R; Corso A; Orlandi E; Bonfichi M; Gotti M; Pascutto C; Mangiacavalli S; Croci G; Fiaccadori V; Morello L; Guerrera ML; Paulli M; Cazzola M
Blood; 2013 Mar; 121(13):2522-8. PubMed ID: 23355535
[TBL] [Abstract][Full Text] [Related]
6. AL amyloidosis with a localized B cell neoplasia.
Stuhlmann-Laeisz C; Schönland SO; Hegenbart U; Oschlies I; Baumgart JV; Krüger S; Röcken C
Virchows Arch; 2019 Mar; 474(3):353-363. PubMed ID: 30680453
[TBL] [Abstract][Full Text] [Related]
7. Significances of MYD88
Meng Q; Cao XX; Li J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):578-582. PubMed ID: 28877839
[TBL] [Abstract][Full Text] [Related]
8. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders.
Ondrejka SL; Lin JJ; Warden DW; Durkin L; Cook JR; Hsi ED
Am J Clin Pathol; 2013 Sep; 140(3):387-94. PubMed ID: 23955458
[TBL] [Abstract][Full Text] [Related]
9. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
[TBL] [Abstract][Full Text] [Related]
10. Light Chain Deposition Disease in a Patient With MYD88 L265P Mutation-positive Low-grade B-cell Lymphoma and Monoclonal Immunoglobulin G κ.
Narita K; Kobayashi H; Suzuki T; Ichikawa D; Yamazaki K; Terawaki H; Suehara Y; Miura D; Takeuchi M; Matsue K
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e805-e808. PubMed ID: 32660905
[No Abstract] [Full Text] [Related]
11. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
[TBL] [Abstract][Full Text] [Related]
12. Synergistic cooperation and crosstalk between
Wang JQ; Jeelall YS; Humburg P; Batchelor EL; Kaya SM; Yoo HM; Goodnow CC; Horikawa K
J Exp Med; 2017 Sep; 214(9):2759-2776. PubMed ID: 28701369
[No Abstract] [Full Text] [Related]
13. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.
King RL; Gonsalves WI; Ansell SM; Greipp PT; Frederick LA; Viswanatha DS; He R; Kyle RA; Gertz MA; Kapoor P; Morice WG; Howard MT
Am J Clin Pathol; 2016 Jun; 145(6):843-51. PubMed ID: 27329639
[TBL] [Abstract][Full Text] [Related]
14. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia.
Jiménez C; Sebastián E; Chillón MC; Giraldo P; Mariano Hernández J; Escalante F; González-López TJ; Aguilera C; de Coca AG; Murillo I; Alcoceba M; Balanzategui A; Sarasquete ME; Corral R; Marín LA; Paiva B; Ocio EM; Gutiérrez NC; González M; San Miguel JF; García-Sanz R
Leukemia; 2013 Aug; 27(8):1722-8. PubMed ID: 23446312
[TBL] [Abstract][Full Text] [Related]
15. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.
Poulain S; Boyle EM; Roumier C; Demarquette H; Wemeau M; Geffroy S; Herbaux C; Bertrand E; Hivert B; Terriou L; Verrier A; Pollet JP; Maurage CA; Onraed B; Morschhauser F; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
Br J Haematol; 2014 Nov; 167(4):506-13. PubMed ID: 25160558
[TBL] [Abstract][Full Text] [Related]
16. Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies.
Bagratuni T; Ntanasis-Stathopoulos I; Gavriatopoulou M; Mavrianou-Koutsoukou N; Liacos C; Patseas D; Kanellias N; Migkou M; Ziogas DC; Eleutherakis-Papaiakovou E; Roussou M; Fotiou D; Terpos E; Kastritis E; Dimopoulos MA
Leukemia; 2018 Dec; 32(12):2617-2625. PubMed ID: 30026568
[TBL] [Abstract][Full Text] [Related]
17. Digital PCR in bone marrow trephine biopsies is highly sensitive for MYD88
Willenbacher E; Willenbacher W; Wolf DG; Zelger B; Peschel I; Manzl C; Haun M; Brunner A
Br J Haematol; 2019 Jul; 186(1):189-191. PubMed ID: 30763982
[No Abstract] [Full Text] [Related]
18.
Yu X; Li W; Deng Q; Li L; Hsi ED; Young KH; Zhang M; Li Y
Cancer Res; 2018 May; 78(10):2457-2462. PubMed ID: 29703722
[TBL] [Abstract][Full Text] [Related]
19. Endomyocardial biopsy with co-localization of a lymphoplasmacytic lymphoma and AL amyloidosis.
Leguit RJ; Vink A; de Jonge N; Minnema MC; Oerlemans MIF
Cardiovasc Pathol; 2021; 53():107348. PubMed ID: 34038803
[TBL] [Abstract][Full Text] [Related]
20. MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL.
Improgo MR; Tesar B; Klitgaard JL; Magori-Cohen R; Yu L; Kasar S; Chaudhary D; Miao W; Fernandes SM; Hoang K; Westlin WF; Kim HT; Brown JR
Br J Haematol; 2019 Mar; 184(6):925-936. PubMed ID: 30537114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
